ATE183515T1 - Zusammensetzungen die die hiv replikation inhibieren - Google Patents

Zusammensetzungen die die hiv replikation inhibieren

Info

Publication number
ATE183515T1
ATE183515T1 AT93917272T AT93917272T ATE183515T1 AT E183515 T1 ATE183515 T1 AT E183515T1 AT 93917272 T AT93917272 T AT 93917272T AT 93917272 T AT93917272 T AT 93917272T AT E183515 T1 ATE183515 T1 AT E183515T1
Authority
AT
Austria
Prior art keywords
hiv
compositions
inhibit hiv
methods
hiv replication
Prior art date
Application number
AT93917272T
Other languages
English (en)
Inventor
Carl T Wild
Thomas J Matthews
Dani P Bolognesi
Original Assignee
Univ Duke
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Duke filed Critical Univ Duke
Application granted granted Critical
Publication of ATE183515T1 publication Critical patent/ATE183515T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT93917272T 1992-07-20 1993-07-19 Zusammensetzungen die die hiv replikation inhibieren ATE183515T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91654092A 1992-07-20 1992-07-20
US92753292A 1992-08-07 1992-08-07

Publications (1)

Publication Number Publication Date
ATE183515T1 true ATE183515T1 (de) 1999-09-15

Family

ID=27129697

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93917272T ATE183515T1 (de) 1992-07-20 1993-07-19 Zusammensetzungen die die hiv replikation inhibieren

Country Status (11)

Country Link
US (3) US5656480A (de)
EP (1) EP0652895B1 (de)
JP (1) JP4010560B2 (de)
KR (1) KR100358209B1 (de)
AT (1) ATE183515T1 (de)
AU (1) AU688733B2 (de)
CA (1) CA2140663C (de)
DE (1) DE69326069T2 (de)
ES (1) ES2139017T3 (de)
NZ (1) NZ254640A (de)
WO (1) WO1994002505A1 (de)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU688733B2 (en) * 1992-07-20 1998-03-19 Duke University Compounds which inhibit HIV replication
US5464933A (en) * 1993-06-07 1995-11-07 Duke University Synthetic peptide inhibitors of HIV transmission
US6479055B1 (en) * 1993-06-07 2002-11-12 Trimeris, Inc. Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission
US6475491B1 (en) * 1995-06-07 2002-11-05 Trimeris, Inc. Treatment of HIV and other viral infections using combinatorial therapy
US6271198B1 (en) 1996-11-06 2001-08-07 Genentech, Inc. Constrained helical peptides and methods of making same
AU6649698A (en) * 1997-01-28 1998-08-18 Regents Of The University Of California, The Peptide probes to coil proteins and methods for making the same
US6818740B1 (en) 1997-04-17 2004-11-16 Whitehead Institute For Biomedical Research Inhibitors of HIV membrane fusion
US6150088A (en) * 1997-04-17 2000-11-21 Whitehead Institute For Biomedical Research Core structure of gp41 from the HIV envelope glycoprotein
US6841657B2 (en) 1997-04-17 2005-01-11 Whitehead Institute For Biomedical Research Inhibitors of HIV membrane fusion
FR2771011B1 (fr) 1997-11-17 2000-01-28 Hippocampe Obtention de vaccins destines a prevenir les effets pathogenes associes a une infection retrovirale
GB9801070D0 (en) * 1998-01-19 1998-03-18 Andaris Ltd HIV inhibition
US6281331B1 (en) * 1998-03-23 2001-08-28 Trimeris, Inc. Methods and compositions for peptide synthesis
US6656906B1 (en) * 1998-05-20 2003-12-02 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
US6258782B1 (en) 1998-05-20 2001-07-10 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
US6747126B1 (en) 1998-07-30 2004-06-08 Whitehead Institute For Biomedical Research Peptide inhibitors of HIV entry
US7960504B2 (en) 1998-07-30 2011-06-14 Whitehead Institute For Biomedical Research Inhibitors of HIV membrane fusion
JP5101764B2 (ja) * 1998-07-30 2012-12-19 ホワイトヘッド インスチチュート フォアー バイオメディカル リサーチ Ｈｉｖ膜融合のインヒビター
CA2359892A1 (en) * 1999-01-08 2000-07-13 Panacos Pharmaceuticals, Inc. Methods of eliciting broadly neutralizing antibodies targeting hiv-1 gp41
BR0010757A (pt) 1999-05-17 2002-02-19 Conjuchem Inc Inibidores de peptìdeo de fusão de longa duração de infecção viral
US6469136B1 (en) * 1999-07-07 2002-10-22 Trimeris, Inc. Methods and composition for peptide synthesis
US6750008B1 (en) * 1999-07-09 2004-06-15 Trimeris, Inc. Methods and compositions for inhibition of membrane fusion-associated events, including HIV transmission
US6541020B1 (en) 1999-07-09 2003-04-01 Trimeris, Inc. Methods and compositions for administration of therapeutic reagents
CA2395291C (en) 1999-12-16 2012-09-11 Whitehead Institute For Biomedical Research Five-helix protein
US20030082525A1 (en) * 1999-12-16 2003-05-01 Whitehead Institute For Biomedical Research Five-Helix protein
EP1264177A2 (de) 2000-02-10 2002-12-11 Panacos Pharmaceuticals, Inc. Verfahren zur detektion von viralen fusionsinhibitoren
US6623741B1 (en) 2000-02-29 2003-09-23 Trimeris, Inc. Methods and compositions for inhibition of membrane fusion-associated events including RSV transmission
US6528308B1 (en) 2000-03-16 2003-03-04 Duke University Suppressor of HIV replication and transcription
NZ521977A (en) * 2000-03-17 2004-05-28 Panacos Pharmaceuticals Inc A method for generating immunogens that elicit neutralizing antibodies against fusion-active regions of HIV envelope proteins
EP1752469B1 (de) * 2001-05-31 2008-10-29 ConjuChem Biotechnologies Inc. Langwirkende Fusionspeptidinhibitoren gegen HIV-Infektion
DK1479691T3 (da) * 2001-05-31 2007-03-12 John Erickson Langvarigt aktive fuionspeptidinhibitorer for HIV infektion
CA2450548C (en) 2001-06-15 2012-05-01 F. Hoffmann-La Roche Ag Method for the recombinant production of peptidic antiviral fusion inhibitors, and acetylation of gb41 fragments
US20030125515A1 (en) * 2001-07-11 2003-07-03 Genfa Zhou End-locked five-helix protein
CN1100564C (zh) * 2001-08-29 2003-02-05 周根发 用于治疗hiv感染的药物、其组合物及其用途
AU2002351176A1 (en) * 2001-11-29 2003-06-17 Mymetics, Corp. Peptides and use thereof in therapeutic agents against hiv infection
US20060241027A1 (en) * 2002-02-07 2006-10-26 Hans-Peter Hauser Hiv inhibiting proteins
US7556813B2 (en) * 2002-09-27 2009-07-07 Trimeris, Inc. Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides
US20040076637A1 (en) * 2002-09-27 2004-04-22 Delmedico Mary Kay HIV-derived HR1 peptides modified to form stable trimers, and their use in therapy to inhibit transmission of human immunodeficiency virus
US7045552B2 (en) * 2002-09-27 2006-05-16 Trimeris, Inc. Pharmaceutical composition for improved administration of HIV gp41-derived peptides, and its use in therapy
US20040132011A1 (en) * 2002-10-16 2004-07-08 Panacos Pharmaceuticals, Inc. Method for detecting viral inactivating agents
CA2443365C (en) * 2002-11-19 2010-01-12 F. Hoffmann-La Roche Ag Methods for the recombinant production of antifusogenic peptides
US20060104988A1 (en) * 2002-12-18 2006-05-18 Pauza C D Vaccines against hiv-1 tat protein to generate neutralizing antibodies
CN1829524A (zh) * 2003-05-08 2006-09-06 波特·W·安德森 基于gp160和人cd4蛋白共有的保守氨基酸序列的抗hiv－1化合物
AU2003265420A1 (en) * 2003-08-14 2005-03-10 The Government Of The United States Of America, As Represented By The Department Of Health And Human Services Polypeptide multimers having antiviral activity
KR20050024730A (ko) * 2003-09-01 2005-03-11 코바이오텍 (주) Ｔ―２０ 펩타이드 코딩 유전자를 포함하는 재조합대장균의 고농도 세포 배양 방법 및 이로부터 생산된ｔ―２０ 펩타이드의 분리 및 정제 방법
WO2005063282A1 (en) 2003-12-23 2005-07-14 Centocor, Inc. Anti-retroviral agents, compositions, methods and uses
EP1701971A2 (de) * 2003-12-31 2006-09-20 F.Hoffmann-La Roche Ag Peptidsynthese unter anwendung eines dekantierungsfilters
EP1701976A2 (de) * 2003-12-31 2006-09-20 F.Hoffmann-La Roche Ag Peptidsynthese und entschützung mit cosolvenz
EP1701970A2 (de) * 2003-12-31 2006-09-20 F.Hoffmann-La Roche Ag Verfahren zur wiedergewinnung eines gespaltenen peptides von einem träger
ATE376556T1 (de) * 2003-12-31 2007-11-15 Hoffmann La Roche Verfahren zur peptidsynthese unter verwendung einer reduzierten menge an entschützungsmittel
WO2005063793A1 (en) * 2003-12-31 2005-07-14 F. Hoffmann-La Roche Ag Process and systems for recovery of peptides
JP2007517522A (ja) * 2004-01-07 2007-07-05 トリメリス，インコーポレーテッド ＨＩＶｇｐ４１ＨＲ２由来の合成ペプチド、およびヒト免疫不全ウイルスの伝播を阻止する治療におけるその使用
CA2565658A1 (en) * 2004-05-06 2005-11-17 Conjuchem Biotechnologies Inc. Compounds for specific viral target
ATE516048T1 (de) * 2004-06-01 2011-07-15 Merck Sharp & Dohme Mit hiv gp41 in wechselwirkung stehende menschliche antikörper
EP2354153A3 (de) 2004-06-01 2012-05-30 Merck Sharp & Dohme Corp. Stabiles Peptidmimetikum des HIV-gp41-Fusionszwischenprodukts
WO2006069779A1 (en) * 2004-12-30 2006-07-06 F. Hoffmann-La Roche Ag Preparing of peptides with excellent solubility
WO2006069697A1 (en) * 2004-12-30 2006-07-06 F. Hoffmann-La Roche Ag Colorimetrically assessing peptide characteristics
EP1833843B1 (de) * 2004-12-30 2009-10-14 F. Hoffmann-La Roche Ag Synthese des peptides t-20 aus peptidfragmenten als zwischenprodukte
CN101133076B (zh) * 2004-12-30 2011-07-13 弗·哈夫曼-拉罗切有限公司 使用肽中间片段合成肽t-1249
EP2314320A2 (de) * 2005-04-05 2011-04-27 Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. Verfahren zur Abschirmung von funktionalen Stellen oder Epitopen von Proteinen
EP1989220B1 (de) 2006-02-02 2011-12-14 Trimeris, Inc. Hiv-fusionshemmerpeptide mit verbesserten biologischen eigenschaften
JP2008005838A (ja) * 2006-05-31 2008-01-17 Wataru Sakamoto 新規ペルオキシダーゼ検出用試薬組成物及びこれを用いた炎症疾患等の判定法および抗酸化活性測定法
TW200817438A (en) * 2006-08-17 2008-04-16 Hoffmann La Roche A conjugate of an antibody against CCR5 and an antifusogenic peptide
KR101105610B1 (ko) 2006-08-17 2012-01-18 에프. 호프만-라 로슈 아게 Ｃｃｒ５ 에 대한 항체 및 항푸소제닉 펩타이드의 컨쥬게이트
ES2535358T3 (es) 2006-12-12 2015-05-08 Biorexis Pharmaceutical Corporation Bibliotecas de proteínas de fusión de transferrina
US20090088378A1 (en) * 2007-01-12 2009-04-02 Omar Quraishi Long lasting inhibitors of viral infection
CL2008000707A1 (es) * 2007-03-13 2008-09-22 Hoffmann La Roche Conjugado de polipeptidos antifusogenicos y polipeptidos derivados de la cabeza globular del factor del complemento c1q; composicion farmaceutica que lo comprende; su uso para tratar infecciones viricas; y metodo de produccion.
BRPI0809995A2 (pt) * 2007-04-03 2015-07-21 Trimeris Inc Composição, e, métodos para a liberação prolongada de um peptídeo em um paciente e para melhorar um sintoma associado com uma infecção por hiv
BRPI0811864A2 (pt) * 2007-05-16 2014-11-18 Conjuchem Biotechnologies Inc Derivados de ácido cistéico de peptídeos antivirais
US20090022720A1 (en) * 2007-07-20 2009-01-22 Stephan Fischer Conjugate of an antibody against CD4 and antifusogenic peptides
BRPI0817697A2 (pt) * 2007-09-25 2015-04-07 Trimeris Inc Método de síntese de um peptídeo, conjunto de fragmentos de peptídeo, e, peptídeo
US9782454B2 (en) 2010-04-22 2017-10-10 Longevity Biotech, Inc. Highly active polypeptides and methods of making and using the same
JP5757639B2 (ja) 2010-09-14 2015-07-29 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ セルピンフィンガー融合ポリペプチド
EP2834264A1 (de) 2012-04-04 2015-02-11 Yeda Research and Development Co. Ltd. Lipopeptidkonjugate mit sphingolipid und aus hiv gp41 gewonnenen peptiden
WO2014145718A2 (en) 2013-03-15 2014-09-18 Longevity Biotech, Inc. Peptides comprising non-natural amino acids and methods of making and using the same

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8305985D0 (en) * 1983-03-04 1983-04-07 Szelke M Enzyme inhibition
DE3788397T3 (de) * 1986-03-24 2003-11-27 Ortho Pharmaceutical Corp., Raritan Synthetische htlv-iii-peptid-zusammensetzungen und ihre verwendung.
US5030449A (en) * 1988-07-21 1991-07-09 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Synthetic vaccine against AIDS virus
EP0323157A3 (de) * 1987-12-24 1990-07-25 The University Of Melbourne Antivirale Verbindungen und Methoden
DE3854425T2 (de) * 1987-12-28 1996-03-07 Yamaha Corp Elfenbeinartiges Tastenmaterial und Verfahren zur Herstellung.
GB8828097D0 (en) * 1988-12-01 1989-01-05 Wellcome Found Peptides
US5444044A (en) * 1992-03-26 1995-08-22 New York Blood Center Synthetic polypeptides as inhibitors of HIV-1
AU688733B2 (en) * 1992-07-20 1998-03-19 Duke University Compounds which inhibit HIV replication
WO1994016109A1 (en) 1993-01-15 1994-07-21 Whitehead Institute For Biomedical Research Membrane fusion events and means for altering same

Also Published As

Publication number Publication date
NZ254640A (en) 1997-04-24
EP0652895A4 (de) 1997-02-05
JPH08500342A (ja) 1996-01-16
AU4683793A (en) 1994-02-14
DE69326069D1 (de) 1999-09-23
AU688733B2 (en) 1998-03-19
KR100358209B1 (ko) 2003-01-24
DE69326069T2 (de) 2000-03-23
CA2140663C (en) 2004-01-27
KR950702575A (ko) 1995-07-29
ES2139017T3 (es) 2000-02-01
EP0652895A1 (de) 1995-05-17
JP4010560B2 (ja) 2007-11-21
US20030181382A1 (en) 2003-09-25
WO1994002505A1 (en) 1994-02-03
EP0652895B1 (de) 1999-08-18
US6573078B1 (en) 2003-06-03
US5656480A (en) 1997-08-12
CA2140663A1 (en) 1994-02-03

Similar Documents

Publication Publication Date Title
DE69326069D1 (de) Zusammensetzungen die die hiv replikation inhibieren
NZ267803A (en) Synthetic peptides which inhibit hiv transmission and other viral diseases
PT1159298E (pt) Péptidos de hiv, antigénios, composições de vacinas, kit de imunoensaio e um método de detecção de anticorpos induzidos por hiv
EP1714974A3 (de) Verfahren und Zusammensetzungen zur Hemmung von mit Membranfusionen in Zusammenhang stehenden Phänomenen, einschliesslich der Übertragung von HIV
DE122005000039I1 (de) DNS-Fragmente des GAG-Gens von LAV
WO2002020554A3 (en) Hiv peptides from conserved regions in gag p17 and 924 and their application in e.g. vaccines
DK0479909T3 (da) Bispecifikke reagenser til AIDS-behandling
ES2053413T1 (es) Peptidos que inducen anticuerpos que neutralizan aislados de vih-1 geneticamente divergentes.
EP0429477A4 (en) Synthetic vaccine against aids virus
BR9607625A (pt) Inibidores de protease retroviral sulfonamida hidroxietilamino de aminoácido heterociclocarbonila
DE3855134D1 (de) Monoklonale menschliche antikörper gegen hiv-i
ES2059577T3 (es) Fragmentos genicos que codifican para las regiones variables de un anticuerpo anti-hiv, anticuerpos anti-hiv quimericos expresados utilizando los mismos y procedimiento para su preparacion.
Chen et al. HIV-1 gp41 binding proteins and antibodies to gp41 could inhibit enhancement of human Raji cell MHC class I and II expression by gp41
EP0656010B8 (de) Verwendung von Peptiden welche eine Immunantwort bewirken zur Herstellung von Medikamenten zur Induzierung der Immunsuppression.
CA2057612A1 (en) Selected peptides of the group-specific antigen (gag) of human immunodeficiency virus (hiv), the preparation and use thereof
DE69133181D1 (de) Design von bioaktiven peptiden auf der basis von immunglobulin strukturen
EP0868536A4 (de) Genetische suppressorelemente gegen hiv
WO2002064154A3 (en) Methods and compositions for inhibiting hiv-coreceptor interactions
AU651113B2 (en) HIV GP120 monoclonal antibodies
EP0491888A4 (en) Immunotherapeutic compositions for treating and preventing aids, arc and hiv infection
AU1275095A (en) Antiviral composition of viral protein trans-dominant variants
Montagnier et al. Monoclonal antibodies to GP110 of HIV and hybridomas secreting these antibodies

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties